| Christina Pierpaoli Parker, PHD | |
|
960 Rocket Way Fl 2, Gardendale, AL 35071-4749 | |
| (205) 443-1725 | |
| Not Available |
| Full Name | Christina Pierpaoli Parker |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 4 Years |
| Location | 960 Rocket Way Fl 2, Gardendale, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902562655 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Alabama Hospital | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Alabama Health Services Foundation, Pc | 1951213107 | 2344 |
News Archive
Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.
In a medical records study covering thousands of children, a U.S.-Canadian team led by researchers at Johns Hopkins Medicine concludes that while surgery to correct congenital heart disease (CHD) within 10 years after birth may restore young hearts to healthy function, it also may be associated with an increased risk of hypertension - high blood pressure - within a few months or years after surgery.
Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Federal health insurance rules are a moving target, and it's unclear whether Republicans will take another run at replacing the Affordable Care Act. In the meantime, some states are staking out strong positions on coverage of abortion, cementing their position regardless of how the federal landscape changes.
› Verified 5 days ago
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.
In a medical records study covering thousands of children, a U.S.-Canadian team led by researchers at Johns Hopkins Medicine concludes that while surgery to correct congenital heart disease (CHD) within 10 years after birth may restore young hearts to healthy function, it also may be associated with an increased risk of hypertension - high blood pressure - within a few months or years after surgery.
Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Federal health insurance rules are a moving target, and it's unclear whether Republicans will take another run at replacing the Affordable Care Act. In the meantime, some states are staking out strong positions on coverage of abortion, cementing their position regardless of how the federal landscape changes.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christina Pierpaoli Parker, PHD 2216 Brookdale Ln, Vestavia Hills, AL 35216-2102 Ph: (205) 207-0374 | Christina Pierpaoli Parker, PHD 960 Rocket Way Fl 2, Gardendale, AL 35071-4749 Ph: (205) 443-1725 |
News Archive
Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.
In a medical records study covering thousands of children, a U.S.-Canadian team led by researchers at Johns Hopkins Medicine concludes that while surgery to correct congenital heart disease (CHD) within 10 years after birth may restore young hearts to healthy function, it also may be associated with an increased risk of hypertension - high blood pressure - within a few months or years after surgery.
Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Federal health insurance rules are a moving target, and it's unclear whether Republicans will take another run at replacing the Affordable Care Act. In the meantime, some states are staking out strong positions on coverage of abortion, cementing their position regardless of how the federal landscape changes.
› Verified 5 days ago